Idoroenyi Amanam to Graft vs Host Disease
This is a "connection" page, showing publications Idoroenyi Amanam has written about Graft vs Host Disease.
Connection Strength
2.690
-
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematology Am Soc Hematol Educ Program. 2023 12 08; 2023(1):164-170.
Score: 0.819
-
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 01; 61(1):82-91.
Score: 0.234
-
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease. Expert Opin Investig Drugs. 2025 May; 34(5):391-400.
Score: 0.226
-
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis. Front Immunol. 2025; 16:1543099.
Score: 0.222
-
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 10; 30(10):1013.e1-1013.e12.
Score: 0.214
-
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 08; 29(8):515.e1-515.e7.
Score: 0.197
-
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 05; 29(5):314-320.
Score: 0.192
-
Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients. Am J Hematol. 2022 11; 97(11):E404-E407.
Score: 0.187
-
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplant. 2022 02; 57(2):232-242.
Score: 0.178
-
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment. Transplant Cell Ther. 2025 Oct; 31(10):824.e1-824.e13.
Score: 0.057
-
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect. Bone Marrow Transplant. 2025 May; 60(5):625-631.
Score: 0.056
-
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024 10; 145:107565.
Score: 0.054
-
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. Bone Marrow Transplant. 2024 Nov; 59(11):1542-1551.
Score: 0.054